Interestingly, a retrospective study found that patients with BMs from NSCLC with different EGFR mutation subtypes (exon 21 and exon 19) will experience different clinical outcomes in EGFR-TKIs alone and EGFR-TKIs combined with RT [46]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.